# A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

> **NCT06789159** · PHASE1 · RECRUITING · sponsor: **Thomas Jefferson University** · enrollment: 30 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma Refractory
- Diffuse Large B Cell Lymphoma Relapsed
- Epstein-Barr Virus (EBV) Infection

## Interventions

- **DRUG:** VK-2019

## Key facts

- **NCT ID:** NCT06789159
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-22
- **Primary completion:** 2028-10-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-10-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06789159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06789159, "A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06789159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*